Cost-effectiveness of HLX01 (Hanlikang(®)) vs. rituximab combined with CHOP in treatment-naive diffuse large B-Cell lymphoma: a partitioned survival model analysis

HLX01（韩利康®）与利妥昔单抗联合CHOP方案治疗初治弥漫性大B细胞淋巴瘤的成本效益分析：基于分区生存模型的分析